PMID- 38039047
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231217
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 22
DP  - 2023 Nov
TI  - Comparing the clinical efficacy and safety of second-line targeted therapy and 
      immunotherapy in patients with mid- to advanced stages of hepatocellular 
      carcinoma - A systematic review and meta-analysis of randomized clinical trials.
PG  - 11156-11168
LID - 34485 [pii]
LID - 10.26355/eurrev_202311_34485 [doi]
AB  - OBJECTIVE: The aim of this study was to examine the efficacy and safety of 
      second-line immunotherapy and targeted treatment in hepatocellular carcinoma 
      (HCC). MATERIALS AND METHODS: From January 2000 to January 2023, ProQuest, 
      PubMed, Web of Science, Scopus, Embase, and the Cochrane Library databases were 
      searched for randomized controlled trials (RCTs) using immunotherapy or targeted 
      therapy as second-line therapy for mid-to-advanced stages of HCC. Overall 
      survival (OS), progression-free survival (PFS), and adverse events (AEs) are all 
      examples of measures of success. RESULTS: This analysis included twenty 
      Randomized Clinical Trials (RCTs) from phases II and III. Collective data 
      revealed better OS with immunotherapy (HR = 0.79; 95% CI: 0.67, 0.93 vs. 0.85; 
      95% CI: 0.78, 0.92), while the targeted therapy played a more effective role in 
      PFS (0.67; 95% CI: 0.56, 0.81). Also, the second-line immunotherapy had a lower 
      odds ratio of AEs of grades 3-5 than the targeted therapy did (OR = 1.75; 95% CI 
      = 0.89, 3.46). CONCLUSIONS: Overall, it appears that targeted medication and 
      immunotherapy as a second-line treatment strategy have generally improved 
      substantially, as well as progression-free survival for patients with 
      mid-to-advanced HCC. Although it is difficult to judge their efficiency, the 
      occurrences of AEs were greater in targeted therapy compared to immunotherapy.
FAU - Li, J-F
AU  - Li JF
AD  - Department of Oncology, Dianjiang People's Hospital of Chongqing, Chongqing, 
      China. leajunfeng@tutanota.com.
FAU - Fu, Y-X
AU  - Fu YX
FAU - Zhang, H-C
AU  - Zhang HC
FAU - Ma, H
AU  - Ma H
FAU - Yuan, G-J
AU  - Yuan GJ
FAU - Tan, Y
AU  - Tan Y
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy/etiology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - Immunotherapy
MH  - *Liver Neoplasms/drug therapy/etiology
EDAT- 2023/12/01 12:43
MHDA- 2023/12/04 12:42
CRDT- 2023/12/01 11:34
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/12/01 12:43 [pubmed]
PHST- 2023/12/01 11:34 [entrez]
AID - 34485 [pii]
AID - 10.26355/eurrev_202311_34485 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Nov;27(22):11156-11168. doi: 
      10.26355/eurrev_202311_34485.